PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

Conclusion These results should be confirmed in a larger patient cohort. PDE4 expression could be an effective potential prognostic factor and therapeutic target for patients with MDS and chronic myelomonocytic leukemia. The role of PDE4 inhibitors should be explored in vitro against MDS cell lines and in preclinical mouse models of MDS. Micro-Abstract PDE4 expression control the inflammation which has an essential role in the pathogenesis of myelodysplastic syndromes (MDS). The expression of each isoform of the PDE4 was evaluated, using transcriptomic profiling, from healthy individuals (n = 10) and patients with MDS (n = 24) or chronic myelomonocytic leukemia (n = 19). PDE4 mean expression was generally higher in MDS than in healthy individuals. Higher PDE4 expression seemed to have a possible negative effect on survival and response to hypomethylating agent (P > .05).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research